The Early Career Mentored Scientist Award provides $65,000 for one year to support PH-related research proposals that were favorably reviewed but not funded by the National Institutes of Health Early Career Award (K award). The grant offers bridge funding to help early-career investigators generate preliminary data needed to strengthen and resubmit their proposals. Letters of intent are due Sept. 22, 2025.

Grant amount: Up to $65,000.
Grant term: One year.
Application timeline

• Applications open: July 1, 2025.
• Letters of intent due: Sept. 22, 2025.
• Review: November 2025.
• Notification to applicants: December 2025.
• Project awarded: January 2026.

How to apply

All applicants must submit a Letter of Intent (LOI) through ProposalCentral during the designated application window. Once LOIs are reviewed, selected applicants will be invited to submit a full application. Each grant cycle will have a dedicated link to the specific funding opportunity, available on the PHA website and ProposalCentral when open.

Proposal requirements: Eligible proposals must have been reviewed within the past year by an NIH study section or similar review body. If submitted more than once, the most recent version must be included. The proposal must:

• Be PH-related.
• Have been submitted to NIH for an Early Career Award such as a K01, K08, K22, K23, KL2, K99/R00, Harold Amos Award, Parker B. Francis Award or the American Heart Association Career Development Award.
• Help advance PH research.

Eligibility

Applicants must be:

• U.S. citizens, permanent residents or non-residents working in a U.S.-based laboratory.
• Non-U.S. citizens must hold a visa that allows them to remain in the country for the duration of the grant.

Applicants may not receive other funding for the same project. If additional support is secured during the grant period, PHA may terminate funding or request adjustments to avoid overlap.

Award recipients must resubmit their proposal to the original funding agency within one year. Proof of resubmission must be included in the final scientific report to PHA.

Additional information

PHA prioritizes diversity, equity and inclusion in science. This award encourages applications from researchers who are part of groups underrepresented in medical and scientific research.

The Health Disparities in PH Research Award supports research that address health inequities in pulmonary hypertension, including early diagnosis, treatment outcomes, access to care and the impact of social determinants of health in adult or pediatric PH. Proposals should identify factors contributing to disparities or propose solutions to improve care for vulnerable and underserved populations. The grant provides up to $50,000 per year for two years. Applications for 2025 are now closed.

Grant amount: Up to $50,000 per year.
Grant term: Up to two years.
Application timeline

• Applications open: Jan. 1, 2025.
• Letters of intent due: April 30, 2025.
• Review: May 2025.
• Notification: July 2025.
• Awards announced: By Aug. 31, 2025.

How to apply

You must submit a letter of intent before applying. A letter of intent form is available in the ProposalCentral application portal under “Download Templates and Instructions.” Email the completed LOI to PHA by April 30, 2025.

Proposal requirements: Projects may be basic, translational or clinical studies that address disparities in adult or pediatric PH. Areas of focus include:

• Societal or economic factors impacting PH health.
• Variations in incidence, care and outcomes due to health disparities.
• Individual behavioral factors contributing to PH.
• Training and education gaps affecting workforce diversity.
• Inequities in access to care in the U.S. and globally.
• Use of PH registries and biorepositories to study social determinants of health.

Eligibility

• Applicants in the U.S. and internationally will be considered.
• Candidates must hold an advanced degree (PhD, MD, DO, PharmD or equivalent), or a doctoral-level clinical degree in public health, health sciences, nursing or allied health.
• Diverse research teams are encouraged. Simultaneous submissions with scientific overlap are allowed, but applicants must notify PHA within one month if multiple projects are funded.

Additional information

PHA prioritizes diversity, equity and inclusion in PH research. Proposals that increase representation and address disparities among underrepresented populations, including but not limited to Black, Latino, Asian, Native American, LGBTQ+, low-income and rural communities, are strongly encouraged.

Submission information

Submit applications online via ProposalCentral.

Contact

Technical support with the online application, email ProposalCentral or call 800-875-2562.

Program questions: Email PHA.

The award supports innovative PH research that might not otherwise be explored without PHA funding. Projects may introduce new scientific or medical paradigms, challenge current thinking or explore problems from new perspectives. The grant provides up to $60,000 per year for two years. Grant applications for 2025 are closed.

Grant amount: Up to $60,000 a year for two years ($120,000 total).
Grant term: Two years.
Application timeline

• Applications open: Feb. 1, 2025.
• Letters of intent are due: May 7, 2025.
• Review: July 2025.
• Notification to applicants: August 2025.
• Project awarded: By September 2025.

How to apply

You must submit a letter of intent before applying. A letter of intent form is available in the ProposalCentral application portal under “Download Templates and Instructions.” Email the completed LOI to PHA by May 7, 2025.

Proposal requirements: The PHA Innovation Research Award supports highly meritorious, innovative projects that could accelerate PH research. New projects may introduce a new scientific or medical paradigm, challenge a current paradigm, or examine an existing problem from a new perspective.

PHA is committed to promoting diversity, equity and inclusion in PH research. Proposals that increase inclusivity, broaden understanding of PH and address health disparities in underrepresented PH patient populations are encouraged. Underrepresented populations include Black, Latino, Asian, Native American, LGBTQ+ individuals, lower socioeconomic groups and underserved geographical regions, including rural areas.

Proposals should reflect diversity, equity and inclusion in study design. PHA encourages diverse research teams that bring together and build on innovative ideas from different perspectives, experiences and backgrounds.

Eligibility

• U.S. citizens, permanent residents or non-residents working at a U.S.-based institution.
• Applicants who are not U.S. citizens but are based in the U.S. must provide proof of employment at a qualified U.S. institution.
• Simultaneous submission of grants with scientific overlap is allowed, but if multiple applications are funded, the applicant must notify the Pulmonary Hypertension Association within one month of formal notification of award. The Research Committee of PHA’s Scientific Leadership Council will assess the degree of overlap.
• In the case of significant scientific overlap, the applicant must choose between the PHA Innovation Research Award and the other grant. Budgetary overlaps are not allowed.
• A principal investigator can have only one PHA grant at a time.

Additional details

PHA’s Scientific Leadership Council Research Committee will review applications and make recommendations to the Pulmonary Hypertension Association Board of Trustees.

Award funding is based on the priority score awarded to each application and the SLC Research Committee’s recommendations.

PHA bases the award on individual and institutional merit. The award is not transferable to another person or institution unless previously approved by PHA.

The PHA Pediatric PH Research Award supports research that addresses unmet needs or expands on areas of limited knowledge in pediatric pulmonary hypertension. This award funds pilot studies that provide foundational research for a larger study and support additional grant submissions. This PHA research award is for one year for up to $65,000. Apply by March 1, 2025.

Grant amount: Up to $65,000.
Grant term: One year.
Application timeline

• Applications open: Jan. 1, 2025.
• Applications due: March 1, 2025.
• Review: April 2025.
• Notification to applicants: May 2025.
• Project awarded: By June 2025.

How to apply

You must submit a letter of intent before applying. A letter of intent form is available in the ProposalCentral application portal under “Download Templates and Instructions.” Email the completed LOI to PHA by May 7, 2025.

Proposal requirements: The award supports pilot studies that lay the groundwork for larger research efforts and future funding opportunities. Areas of focus include, but are not limited to:

• Developmental lung disease.
• Pulmonary vascular disease that leads to PH.
• Signaling pathways regulating pulmonary vascular remodeling in pediatric PAH.
• Classification, diagnosis and treatment of pediatric PH.
• Improved clinical trial designs and new endpoints or biomarkers.
• Pediatric PH quality improvement and care initiatives.

Eligibility

• Applicants must be U.S. citizens, permanent residents or non-residents working at a U.S.-based institution.
• Non-citizens must provide evidence of employment at a qualified U.S. institution. Simultaneous submission of grants with scientific overlap is allowed, but awardees must notify PHA within one month of multiple fundings.
• Awards are based on individual and institutional merits.
• Awards are not transferable unless previously approved by PHA.

Additional details

PHA’s Scientific Leadership Council Research Committee will review all applications and make recommendations to the PHA Board of Trustees. Funding decisions are based on priority scores and committee recommendations.